Coverage summary
Aardvark Labs Capital Research has covered Novartis AG (NVS) since October 29, 2025. The company is in the Healthcare sector. This page lists 5 reports: 5 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published October 31, 2026. The current rating is Hold, the same in every report since coverage began.
Translations: 4 in Chinese.
The Excel model for NVS holds 14 quarters and 3 fiscal years of history and 10 quarters and 5 fiscal years of projections. It was last updated September 28, 2026.
All NVS reports
Recap: Q3 2026
Novartis Raises Its Profit Guide in the Quarter Two of Its Three Big Bets Failed
Recap: Q2 2026
Novartis Returns to Growth, Then Tells You Five Points of It Reverse in the Second Half
Recap: Q1 2026
Novartis Misses in the Exact Shape It Guided, While Net Debt Adds $16 Billion in Ninety Days
Recap: Q4 2025
Novartis Clears the 40% Margin Bar Two Years Early, Then Guides to Its First Core Profit Decline in Five Years
Recap: Q3 2025
The Cliff Arrives: Novartis Decelerates From 21% to 7%, Then Tells the Street Its 2026 Numbers Are Too High